Vanadium (V)

Vanadium is a trace transition metal that exists in several oxidation states, with vanadyl (V4+) and vanadate (V5+) being the most biologically relevant [7, 10, 13]. It is not a biological macromolecule target in the traditional therapeutic sense (such as a receptor or enzyme); rather, it is a pharmacological agent that acts upon multiple molecular targets, most notably Protein Tyrosine Phosphatases (PTPs) [1, 2, 5]. Vanadium compounds, such as vanadyl sulfate and organic oxovanadium complexes, mimic the structure of the phosphate group, allowing them to compete for the active sites of phosphatases like PTP1B [4, 17]. This inhibition leads to the sustained phosphorylation of the insulin receptor and downstream signaling proteins, facilitating insulin-mimetic effects such as improved glucose uptake and glycogen synthesis in diabetic models [11, 12, 14]. Beyond its role in metabolic regulation, vanadium compounds have been explored for potential anti-tumor and anti-parasitic properties, involving the modulation of oxidative stress and the inhibition of various ATPases [13, 16, 18]. However, the clinical development of vanadium-based therapies is severely limited by its toxicity profile, which includes severe gastrointestinal irritation, potential renal damage, and adverse effects on the central nervous system [6, 8, 9, 16].

Other names

VanadateVanadylMetavanadateOrthovanadateOxovanadiumPervanadate

Vanadium acts primarily as a phosphate mimetic, inhibiting Protein Tyrosine Phosphatases (PTPs) such as PTP1B by stabilizing a transition-state intermediate during dephosphorylation. It also inhibits various P-type ATPases and can trigger the production of reactive oxygen species (ROS) through Fenton-like chemistry, leading to the modulation of signaling pathways like PI3K/AKT and MAPK/ERK [1, 13, 15, 17].